Manja Friese-Hamim

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Dna Damage Response

Top Venues

Cancer research communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Michaela Poliaková Turan, Rahel Riedo, Matúš Medo, Chiara Pozzato, Manja Friese-Hamim, Jonas Paul Koch, Si'Ana A Coggins, Qun Li, Baek Kim, Joachim Albers, Daniel Matthias Aebersold, Nicola Zamboni, Yitzhak Zimmer, Michaela Medová
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. Cancer research communications 4 (7) (2024)
Michaela Poliaková Turan, Rahel Riedo, Matúš Medo, Chiara Pozzato, Manja Friese-Hamim, Jonas Paul Koch, Si'Ana A Coggins, Qun Li, Baek Kim, Joachim Albers, Daniel Matthias Aebersold, Nicola Zamboni, Yitzhak Zimmer, Michaela Medová
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. Cancer research communications 4 (7) (2024)
Michaela Poliaková Turan, Rahel Riedo, Matúš Medo, Chiara Pozzato, Manja Friese-Hamim, Jonas Paul Koch, Si'Ana A Coggins, Qun Li, Baek Kim, Joachim Albers, Daniel Matthias Aebersold, Nicola Zamboni, Yitzhak Zimmer, Michaela Medová
E2F1-associated purine synthesis pathway is a major component of the MET-DNA damage response network. Cancer research communications (2024)
Michaela Poliaková Turan, Rahel Riedo, Matúš Medo, Chiara Pozzato, Manja Friese-Hamim, Jonas Paul Koch, Si'Ana A Coggins, Qun Li, Baek Kim, Joachim Albers, Daniel Matthias Aebersold, Nicola Zamboni, Yitzhak Zimmer, Michaela Medová
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. Cancer research communications 4 (7) (2024)
Manja Friese-Hamim, Maria J Ortiz-Ruiz, Olga Bogatyrova, Marina Keil, Felix Rohdich, Beatrix Blume, Birgitta Leuthner, Frank Czauderna, Diane Hahn, Julia Jabs, Frank Jaehrling, Timo Heinrich, Roland Kellner, Katherine Chan, Amy H Y Tong, Dirk Wienke, Jason Moffat, Andree Blaukat, Frank T Zenke
Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models. Molecular cancer therapeutics (2023)
Joachim Albers, Manja Friese-Hamim, Anderson Clark, Oliver Schadt, Gina Walter-Bausch, Christopher Stroh, Andreas Johne, Niki Karachaliou, Andree Blaukat
The preclinical pharmacology of tepotinib - a highly selective MET inhibitor with activity in tumors harboring MET alterations. Molecular cancer therapeutics (2023)